Table 1. Patient Characteristics... | American Society of Hematology

Table 1.

Patient Characteristics

Variable	N
Diagnosis
AML	28
ALL	13
Patient/donor sex
Male/male	9
Male/female	13
Female/female	7
Female/male	12
Age
Patient	34 (22-54)
Donor	34 (16-51)
HLA disparity
Matched	34
Mismatched	7
1 antigen	6
2 antigens	1
Ablative regimen
Cyclophosphamide/TBI (1,300 cGy)	4
Cyclophosphamide/TBI (1,400 cGy)	26
Cyclophosphamide/TBI (1,480 cGy)	7
Cyclophosphamide/TBI (1,560 cGy)	2
Cyclophosphamide/Busulfan	1
Cell dose
Median BM cells infused	5.6 × 10⁷ cells/kg
Median CD3⁺ BM cells infused	1.5 × 10⁶ cells/kg

Variable	N
Diagnosis
AML	28
ALL	13
Patient/donor sex
Male/male	9
Male/female	13
Female/female	7
Female/male	12
Age
Patient	34 (22-54)
Donor	34 (16-51)
HLA disparity
Matched	34
Mismatched	7
1 antigen	6
2 antigens	1
Ablative regimen
Cyclophosphamide/TBI (1,300 cGy)	4
Cyclophosphamide/TBI (1,400 cGy)	26
Cyclophosphamide/TBI (1,480 cGy)	7
Cyclophosphamide/TBI (1,560 cGy)	2
Cyclophosphamide/Busulfan	1
Cell dose
Median BM cells infused	5.6 × 10⁷ cells/kg
Median CD3⁺ BM cells infused	1.5 × 10⁶ cells/kg